Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol

Cover Page

Cite item

Full Text

Abstract

   The bispecific monoclonal antibody blinatumomab (CD19/CD3) is widely and successfully used to treat children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Advances have also led to the use of immunotherapy in children with primary BCP-ALL. This paper presents the effectiveness of a single blinatumomab course instead of consolidation chemotherapy and with short maintenance therapy in primary BCP-ALL patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Between February 2020 and November 2022, 165 children with non-high-risk BCP-ALL (according to clinical stratification criteria defined in the study) were enrolled in the ALL-MB 2019 pilot study (NCT04723342). Patients received conventional risk-adapted induction therapy according to the ALL-MB 2015 protocol. Those who achieved complete morphological remission at the end of induction received 15 µg/m2/day of blinatumomab immediately after induction for 4 weeks, followed by 12 months of maintenance therapy. Minimal residual disease (MRD) was measured using multicolor flow cytometryat the end of induction, then immediately after blinatumomab course, and then four times during maintenance therapy at threemonth intervals. All 165 patients successfully completed induction therapy and achieved complete hematological remission. All had their MRD measured at the end of induction. One hundred thirty-six (82.2%) patients were MRD-negative, and the remaining 29 patients showed various levels of MRD positivity. MRD was assessed in all 164 patients who completed the blinatumomab course. One patient had blinatumomab discontinued due to acute neurotoxicity and was subsequently treated according to the intermediate-risk ALL-MB 2015 protocol. All but one patient achieved MRD negativity after blinatumomab course, regardless of MRD value at the end of induction. One adolescent girl with a high MRD level after induction remained MRD positive after blinatumomab course and further received high-risk therapy with allogeneic hematopoietic stem cell transplantation. At the time of analysis, 162 children had completed all therapy, including 12 months of maintenance. MRD was examined in 151 of them, and all were MRD negative. Over a 4-year study period with a median follow-up of 2.5 years, 10 relapses were registered: 4 in the standard-risk group and 6 in the intermediate-risk group. The 4-year event-free survival was 89.1 ± 3.7 % for all patients, 92.0 ± 4.2 % and 82.8 ± 8.1 % for the standard and intermediate risk groups, respectively. At the time of analysis, all patients were alive; no deaths were registered. Although the presented results are preliminary and more time is needed for definitive conclusions, a 4-week 15 µg/m2/day blinatumomab course immediately after induction followed by 12 months of maintenance therapy is effective in achieving and maintaining MRD negativity in children with non-high risk BCP-ALL. This study showed the fundamental possibility of treating ALL by combining immunotherapy with the bispecific monoclonal antibody blinatumomab with a significant chemotherapy reduction.

About the authors

A. I. Karachunskiy

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation; The N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: aikarat@mail.ru
ORCID iD: 0000-0002-9300-198X

Alexander I. Karachunskiy, Dr. Med. Sci., Professor, Deputy Director General, Director

Institute of Oncology, Radiology and Nuclear Medicine

117997; 1 Samory Mashela St.; Moscow

Russian Federation

Yu. V. Rumyantseva

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation; The N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-9670-3728

Moscow

Russian Federation

L. I. Zharikova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation; The N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-1105-8676

Moscow

Russian Federation

O. I. Bydanov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

ORCID iD: 0000-0003-3232-2322

Moscow

Russian Federation

S. N. Lagoyko

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

ORCID iD: 0000-0002-3793-104X

Moscow

Russian Federation

A. M. Popov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

ORCID iD: 0000-0002-0889-6986

Moscow

Russian Federation

E. V. Mikhailova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

ORCID iD: 0000-0002-3450-0498

Moscow

Russian Federation

Yu. V. Olshanskaya

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

ORCID iD: 0000-0002-2352-7716

Moscow

Russian Federation

E. A. Zerkalenkova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Moscow

Russian Federation

N. V. Myakova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

ORCID iD: 0000-0002-4779-1896

Moscow

Russian Federation

D. V. Litvinov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation; The N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-7461-0050

Moscow

Russian Federation

M. I. Abu-Dzhabal

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Moscow

Russian Federation

L. A. Khachatryan

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

ORCID iD: 0000-0001-7265-0414

Moscow

Russian Federation

A. V. Pshonkin

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

Moscow

Russian Federation

N. I. Ponomareva

Russian Children's Clinical Hospital ‒ branch of the N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

Moscow

Russian Federation

Yu. V. Dinikina

The V.A. Almazov National Medical Research Centre of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-2003-0982

Saint Petersburg

Russian Federation

T. T. Valiev

The L.A. Durnov Research Institute of Pediatric Oncology and Hematology, the N.N. Blokhin National Medical Research Center of Oncology of Ministry of Healthcare of the Russian Federation

Moscow

Russian Federation

S. R. Varfolomeeva

The L.A. Durnov Research Institute of Pediatric Oncology and Hematology, the N.N. Blokhin National Medical Research Center of Oncology of Ministry of Healthcare of the Russian Federation

Moscow

Russian Federation

G. A. Novichkova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthсare of the Russian Federation

ORCID iD: 0000-0002-2322-5734

Moscow

Russian Federation

References

  1. Rumyantseva Yu.V, Karachunskiy A.I The optimization of treatment for acute lymphoblastic leukemia in children in Russia and Belarus: Moscow–Berlin strategy. Pediatric Hematology/Oncology and Immunopathology 2007; 6 (4):13‒22. (In Russ.)
  2. Karachunskiy A., Herold R., von Stackelberg A., Miakova N., Timakow A., Mahortih T., et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia 2008; 22(6): 1144‒1153. doi: 10.1038/leu.2008.63
  3. Hunger S.P., Lu X., Devidas M., Camitta B.M., Gaynon P.S., Winick N.J., et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group. J Clin Oncol 2012; 30 (14): 1663‒9. doi: 10.1200/JCO.2011.37.8018
  4. Raetz E., Lu X., Devidas M., Loh M., Winick N., Carroll W., et al. Continued improvements in overall survival (OS) in children with newly diagnosed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) report. Pediatr Blood Cancer 2018; 65 (Suppl 1): e27057.
  5. Toft N., Birgens H., Abrahamsson J., Griškevičius L., Hallböök H., Heyman M., et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia 2018; 32 (3): 606‒15. doi: 10.1038/leu.2017.265
  6. Moorman A.V., Antony G., Wade R., Butler E.R., Enshaei A., Harrison C.J., et al. Time to cure for childhood and young adult acute lymphoblastic leukemia is independent of early risk factors: Long-term follow-up of the UKALL2003 trial. J Clin Oncol 2022; 40 (36): 4228‒39. doi: 10.1200/JCO.22.00245
  7. Pieters R., Mullighan C.G., Hunger S.P. Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL. J Clin Oncol 2023; 41 (36): 5579‒91. doi: 10.1200/JCO.23.01286
  8. Robison L.L., Bhatia S. Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 2003; 122 (3): 345‒59. doi: 10.1046/j.1365-2141.2003.04499.x
  9. Schmiegelow K., Attarbaschi A., Barzilai S., Escherich G., Frandsen T.L., Halsey C., et al. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol 2016; 17 (6): e231‒9. doi: 10.1016/S1470-2045(16)30035-3
  10. Schmiegelow K., Müller K., Mogensen S.S., Mogensen P.R., Wolthers B.O., Stoltze U.K., et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res 2017; 6: 444. doi: 10.12688/f1000research.10768.1
  11. Viardot A., Locatelli F., Stieglmaier J., Zaman F., Jabbour E. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol 2020; 99 (10): 2215‒29. doi: 10.1007/s00277-020-04221-0
  12. Brown P.A., Ji L., Xu X., Devidas M., Hogan L.E., Borowitz M.J., et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA 2021; 325 (9): 833‒42. doi: 10.1001/jama.2021.0669
  13. Locatelli F., Zugmaier G., Rizzari C., Morris J.D., Gruhn B., Klingebiel T., et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA 2021; 325 (9): 843‒54. doi: 10.1001/jama.2021.0987
  14. Locatelli F. Blinatumomab before allogeneic stem cell transplantation: the ideal strategy to improve patient's outcomes? Transplant Cell Ther 2024; 30 (2): 129‒30. doi: 10.1016/j.jtct.2024.01.061
  15. Queudeville M., Ebinger M. Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review). J Clin Med 2021; 10 (12): 2544. doi: 10.3390/jcm10122544
  16. Hodder A., Mishra A.K., Enshaei A., Baird S., Elbeshlawi I., Bonney D., et al. Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL. J Clin Oncol 2023: JCO2301392. Epub ahead of print. doi: 10.1200/JCO.23.01392
  17. Popov A.M., Verzhbitskaya T.Yu., Movchan L.V., Demina I.A., Mikhailova E.V., Semchenkova A.A., et al. Flow cytometry in acute leukemia diagnostics. Guidelines of Russian–Belarusian multicenter group for pediatric leukemia studies. Pediatric Hematology/Oncology and Immunopathology 2023; 22 (1): 165–77. doi: 10.24287/1726-1708-2023-22-1-165-177 (In Russ.).
  18. Tsaur G.А., Olshanskaya Yu.V., Obukhova T.N., Sudarikov A.B., Lazareva O.V., Gindina T.L. Cytogenetic and molecular genetic diagnostics in oncohematological disorders: a position paper of the Organization of Molecular Geneticists in Oncology and Oncohematology. Russian journal of hematology and transfusiology 2023; 68 (1): 129–43. doi: 10.35754/0234-5730-2023-68-1-129-143 (In Russ.)
  19. Mikhailova E.V., Illarionova O.I., Maschan M.A., Novichkova G.A., Karachunskiy A.I., Popov A.M. Guidelines for the flow cytometric minimal residual disease monitoring in B-lineage acute lymphoblastic leukemia after CD19-directed immunotherapy. Pediatric Hematology/Oncology and Immunopathology 2023; 22 (2): 175–84. doi: 10.24287/1726-1708-2023-22-2-175-184 (In Russ.)
  20. Mikhailova E., Illarionova O., Komkov A., Zerkalenkova E., Mamedov I., Shelikhova L., et al. Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy. Cancers (Basel) 2022; 14 (21): 5445. doi: 10.3390/cancers14215445
  21. Mikhailova E.V., Verzhbitskaya T.Yu., Roumiantseva J.V., Illarionova O.I., Semchenkova A.A., Fechina L.G., et al. The influence of a dosage regimen of dexamethasone on detection of normal B-cell precursors in the bone marrow of children with BCP-ALL at the end of induction therapy. Pediatric Hematology/Oncology and Immunopathology 2020; 19 (1): 53–7. doi: 10.24287/1726-1708-2020-19-1-53-57 (In Russ.)
  22. Suprun R.N., Rumyantseva Yu.V., Bydanov O.I., Zharikova L.I., Lagoiko S.N., Lebedev V.V. et al. Acute lymphoblastic leukemia in children with Down syndrome: comparative analysis of treatment results according to ALL-MB 2008 and ALL-MB 2015 protocols. Russian Journal of Pediatric Hematology and Oncology 2022; 9 (3): 12–31. doi: 10.21682/2311-1267-2022-9-3-12-31 (In Russ.)
  23. Popov A., Henze G., Roumiantseva J., Budanov O., Belevtsev M., Verzhbitskaya T., et al. A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurement. Pediatr Blood Cancer 2023; 70 (6): e30295. doi: 10.1002/pbc.30295
  24. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
  25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50 (3): 163‒70.
  26. Kalbfleisch J., Prentice R. The Statistical Analysis of Failure Time Data. Wiley, New York; 2002.
  27. Cortese G., Andersen P.K. Competing risks and time-dependent covariates. Biom J 2010; 52 (1): 138‒58. doi: 10.1002/bimj.200900076
  28. Popov A., Henze G., Roumiantseva J., Budanov O., Belevtsev M., Verzhbitskaya T., et al. One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 study. J Cancer Res Clin Oncol 2023; 149 (8): 4629‒37. doi: 10.1007/s00432-022-04378-3
  29. Clements J.D., Zhu M., Kuchimanchi M., Terminello B., Doshi S. Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. Clin Pharmacokinet 2020; 59 (4): 463–74. doi: 10.1007/s40262-019-00823-8
  30. Chitadze G., Laqua A., Lettau M., Baldus C.D., Brüggemann M. Bispecific antibodies in acute lymphoblastic leukemia therapy. Expert Rev Hematol 2020; 13 (11): 1211‒33. doi: 10.1080/17474086.2020.1831380
  31. von Stackelberg A., Locatelli F., Zugmaier G., Handgretinger R., Trippett T.M., Rizzari C., et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol 2016; 34 (36): 4381‒9. doi: 10.1200/JCO.2016.67.3301
  32. van der Sluis I.M., de Lorenzo P., Kotecha R.S., Attarbaschi A., Escherich G., Nysom K., et al. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. N Engl J Med 2023; 388 (17): 1572‒81. doi: 10.1056/NEJMoa2214171
  33. Popov A., Fominikh V., Mikhailova E., Shelikhova L., Tsaur G., Abugova Y., et al. Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants. Br J Haematol 2021; 194 (1): 174‒8. doi: 10.1111/bjh.17466
  34. Popov A., Henze G., Roumiantseva J., Budanov O., Belevtsev M., Verzhbitskaya T., et al. A simple algorithm with one flow cytometric MRD measurement identifies more than 40 % of children with ALL who can be cured with low-intensity therapy. The ALL-MB 2008 trial results. Leukemia 2022; 36 (5): 1382‒5. doi: 10.1038/s41375-022-01542-z
  35. Popov A., Henze G., Roumiantseva Yu., Budanov O., Belevtsev M., Verzhbitskaya T., et al. Low-intensity therapy cures over 40 % of children with rapid Flow-MRD responding ALL: the ALL-MB 2008 trial results. Pediatric Hematology/Oncology and Immunopathology 2022; 21 (2): 95–104. doi: 10.24287/1726-1708-2022-21-2-95-104

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Karachunskiy A.I., Rumyantseva Y.V., Zharikova L.I., Bydanov O.I., Lagoyko S.N., Popov A.M., Mikhailova E.V., Olshanskaya Y.V., Zerkalenkova E.A., Myakova N.V., Litvinov D.V., Abu-Dzhabal M.I., Khachatryan L.A., Pshonkin A.V., Ponomareva N.I., Dinikina Y.V., Valiev T.T., Varfolomeeva S.R., Novichkova G.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.